Live Breaking News & Updates on Gregory vidal

Stay informed with the latest breaking news from Gregory vidal on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Gregory vidal and stay connected to the pulse of your community

Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.

William-gradishar , Gregory-vidal , Rena-callahan , Mabel-mardones , Peer-exchange , European-society-for-medical-oncology-congress , Medical-oncology-congress , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances

OneOncology Partners With Clearview Cancer Institute and Names New Disease Group Chairs; FCS Appoints Executive Board Members

Business and practice updates from our Strategic Alliance Partners.

Decatur , Alabama , United-states , Tennessee , Florida , Scottsboro , New-york , Piedmont , Maen-hussein , Hoffmane-oneoncology , Alfredo-torres , Lucion-gordan

Elacestrant: Treatment Considerations, Including Dosing and Compliance

Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.

William-gradishar , Mabel-mardones , Rena-callahan , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Rena-callahan , William-gradishar , Mabel-mardones , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.

William-gradishar , Rena-callahan , Mabel-mardones , Gregory-vidal , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

Experts explore the efficacy and safety profiles of elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advantages in metastatic breast cancer treatment.

Rena-callahan , Gregory-vidal , William-gradishar , Mabel-mardones , Peer-exchange , Oral-serd , Mbc , Metastatic-breast-cancer , Serd , Therapeutic-advances , Panel-discussion , Er-positive

Treatment Options for Newly Diagnosed or Recurrent Breast Cancer Subset

An expert explained the different treatment options for patients with estrogen receptor-positive, HER2-negative breast cancer that has recently been diagnosed or has recurred.

Gregory-vidal , Cancer-center , Research-institute-in-memphis , University-of-tennessee-health-science-center , West-cancer-center , Research-institute , One-oncology , Tennessee-health-science-center , Educated-patient , Metastatic-breast , News , Breast-cancer

Understanding a Metastatic Breast Cancer Diagnosis and the Role of Biomarker Testing

An expert explained how next-generation sequencing can help patients with metastatic breast cancer understand their disease and available treatment options.

Gregory-vidal , Cancer-center , University-of-tennessee-health-science-center , Research-institute-in-memphis , West-cancer-center , Research-institute , One-oncology , Tennessee-health-science-center , Educated-patient , Metastatic-breast , News , Breast-cancer

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

Over the past 10 years, data from studies including the TAILORx and RxPONDER studies have reshaped treatment standards for patients with hormone receptor–positive, HER2-negative breast cancer.

United-states , American , Timothyj-pluard , Aditya-bardia , Hyun-kim , Komal-jhaveri , Gregory-vidal , American-society-of-clinical-oncology , Onclive-peer-exchange , Onclive-peer , Clinical-oncology , Annual-meeting

Practical Considerations for ADC Selection in HR+/HER2- mBC

Practical Considerations for ADC Selection in HR+/HER2- mBC
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Gregory-vidal , Aditya-bardia , Komal-jhaveri ,